PetVivo raises ~$1.8M via registered direct offering of 1.2M shares at $1.50, with warrants

PetVivo Holdings, Inc.

Securities Purchase Agreement with two accredited investors closed Aug 9, 2023.
1,200,002 shares sold at $1.50 each; net proceeds ~$1,775,000 after $25,000 expenses.
Concurrent private placement of warrants to purchase 1,200,002 shares at $2.00, exercisable after 6 months, expiring 3 years later.
Proceeds to fund commercialization of Spryng with OsteoCushion Technology, clinical trials, and working capital.
Offering directly placed, no underwriter; warrants are unregistered under the Securities Act.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

PetVivo Holdings, Inc. entered into Securities Purchase Agreement with two accredited investors valued at 1,200,002 shares of common stock at $1.50 per share and warrants to purchase 1,200,002 shares (effective 2023-08-04).

Action: entry
Agreement: equity purchase
Counterparty: two accredited investors
Value: 1,200,002 shares of common stock at $1.50 per share and warrants to purchase 1,200,002 shares
Effective: 2023-08-04

Exact text from the filing

On August 4, 2023, PetVivo Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a two accredited investors (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investors in a registered direct offering (the “Registered Offering”) 1,200,002 shares (“Registered Shares”) of the Company’s common stock (the “Common Stock”) at a price of $1.50 per share.

View on SEC.gov

Browse all material agreements →

PetVivo Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027334

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.